Interactions between treatment and continuous covariates: A step toward individualizing therapy

Journal of Clinical Oncology

Volumn 26, Issue 9, 2008, Pages 1397-1399

  Royston, Patrick ^a   Sauerbrei, Willi ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CMF REGIMEN; TUMOR MARKER; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; COVARIANCE; DISEASE FREE SURVIVAL; EDITORIAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; BLOOD; BREAST TUMOR; CHEMISTRY; KAPLAN MEIER METHOD; KIDNEY TUMOR; LEUKOCYTE COUNT; NOTE; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; LEUKOCYTE COUNT; METHOTREXATE; MODELS, STATISTICAL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 41149159651     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.8981     Document Type: Editorial

References (9)

1. Assmann SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355:1064-1069, 2000
2. Viale G, Regan MM, Maiorano E, et al: Chemoendocrine versus endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. J Clin Oncol 26:1404-1410, 2008
3. Bonetti M, Gelber RD: A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595-2609, 2000
4. Bonetti M, Gelber RD: Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465-481, 2004
5. Royston P, Sauerbrei W: A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 23:2509-2525, 2004
6. Sauerbrei W, Royston P, Bojar H, et al: Modelling the effects of standard prognostic factors in node positive breast cancer. Br J Cancer 79:1752-1760, 1999
7. Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90:794-799, 2004
8. Sauerbrei W, Royston P, Zapien K: Detecting an interaction between treatment and a continuous covariate: A comparison of two approaches. Comp Statist Data Anal 51:4054-4063, 2007
9. Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: A bad idea. Stat Med 25:127-141, 2006